Heart Failure

The “ABCs” have provided a roadmap for primary and secondary CVD prevention since 1999, according to a speaker at the virtual American Society for Preventive Cardiology Congress on CVD Prevention.

Patients with HF and CAD who increased their daily levels of physical activity after receiving an implantable cardioverter defibrillator had better 1-year survival vs. those who did not, researchers reported.

A strategy of care based on lung ultrasound in the ED for pulmonary congestion in acute HF showed no benefit in reducing B-line numbers compared with usual care, according to new study findings.

In a cohort of patients with HF with reduced ejection fraction, those who received sacubitril/valsartan demonstrated decreased pulmonary artery pressures at 30 days compared with those who did not receive it, researchers reported.

Doctors at Duke University Hospital performed the first North American implantation of a next-generation total artificial heart. The 39-year-old patient is recovering well after the 8-hour procedure, doctors said.

Cytokinetics announced a phase 2 trial of its novel cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy was successful.

The effects of the SGLT2 inhibitor empagliflozin varied depending on region and racial/ethnic group, with the most benefit observed in those with the highest ratios of HF hospitalization to CV death, according to EMPEROR-Reduced trial data.

Duke University and Carmat announced that doctors at Duke University Hospital performed the first North American implantation of a next-generation total artificial heart.

Among individuals with HF with reduced ejection fraction and iron deficiency who were implanted with a cardiac resynchronization therapy device, ferric carboxymaltose improved cardiac function, including left ventricular EF.

Pirfenidone vs. placebo in patients with HF, EF at least 45% and elevated natriuretic peptide levels.